Decoy Biosystems, Inc.

Vaxiion Therapeutics, LLC

Novo Nordisk A/s

Shanghai Institute of Pharmaceutical Industry

Indaptus Therapeutics, Inc.

Michael James Newman

Matthew J Giacalone

Jesper F Lau

Henrik Sune Andersen

Yan Li

Ole Hvilsted Olsen

Ying Liu

Tong Wu

Thomas Kruse Hansen

Yu Ge

Farid Bakir

Daniel Dale Holsworth

Frank Urban Axe

Quanhai Liu

Luke Milburn Judge

Roy Teruyuki Uyeda

Barry Zvi Shapira

Yan Qin

Zhiru Xu

Min-yu Liu

Niels Peter Hundahl Moller

The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non-viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines.

Methods of treatment of infections using bacteria

Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.

Compositions and methods for treatment of cancer using bacteria

The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.

Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells

A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases.

Therapeutic formulations based on asiatic acid and selected salts thereof

Modulators of protein tyrosine phosphatases (PTPases)

Growing community of inventors

San Diego, CA, United States of America

Michael James Newman